Out-of-pocket caps are annual limits on what an insured person pays for covered, generally in-network care, but they are not a universal ceiling on the cost of expensive medicines. For patients using specialty drugs, the practical benefit depends on the plan’s deductible, coinsurance, formulary, coverage rules, and whether the medicine is covered at all. The Affordable Care Act set a 2025 maximum of $9,200 for an individual and $18,400 for a family in most non-grandfathered commercial plans, while Medicare Part D introduced a $2,000 prescription-drug out-of-pocket limit in 2025. These protections can prevent catastrophic bills, but patients may still face thousands of dollars early in the year, continuing premiums, noncovered-drug costs, or affordability problems when treatment is interrupted.

Out-of-Pocket Cap—Annual Patient Cost Ceiling

An out-of-pocket cap, also called an out-of-pocket maximum or limit, is the most a covered member must pay during a plan year for covered health services under the plan’s cost-sharing rules. The Centers for Medicare & Medicaid Services defines the limit as a ceiling that generally includes deductibles, copayments, and coinsurance for covered benefits, but excludes premiums, balance-billing charges, and services the plan does not cover.

The key distinction is between a maximum liability for covered care and a maximum price for every medicine a person needs. A drug may not count toward the cap if it is excluded from the formulary, obtained outside the plan’s network, purchased without required authorization, or paid entirely by the patient. Even when the drug is covered, the patient may have to spend the deductible and a substantial share of the drug’s negotiated price before reaching the limit.

Commercial-plan caps

For 2025, CMS set the annual cost-sharing limit for most Affordable Care Act-compliant individual and family plans at $9,200 for self-only coverage and $18,400 for other-than-self-only coverage. The limit applies to essential health benefits and generally to in-network care. Employer plans can have different designs, although federal rules still restrict the maximum for many nongrandfathered plans.

For someone taking a specialty medicine priced at several thousand dollars per month, the cap may stop covered cost sharing after the patient reaches it. It does not necessarily make the first prescription affordable. A plan could require a $2,000 deductible followed by 20% or 30% coinsurance on a drug whose monthly allowed cost is $10,000. The patient could therefore reach the annual limit rapidly, but still need access to several thousand dollars at the beginning of the treatment year.

Medicare Part D’s prescription-drug limit

Medicare Part D changed substantially under the Inflation Reduction Act. Beginning in 2025, a Part D enrollee’s annual out-of-pocket spending for covered prescription drugs is limited to $2,000, indexed in later years. The law also allows beneficiaries to spread their covered prescription-drug costs across the year through the Medicare Prescription Payment Plan rather than paying large amounts in a single month.

This is a meaningful protection for people taking high-cost medicines, but it is narrower than a general medical out-of-pocket maximum. It applies to covered Part D drugs and does not automatically cover premiums, drugs paid under a different Medicare benefit, or medicines excluded by the plan. A person using a physician-administered biologic billed under Medicare Part B may face a different cost-sharing structure, including supplemental insurance or assistance programs.

Medicaid and other public coverage

Medicaid generally provides stronger protection against large prescription-drug bills than commercial insurance, with federal rules limiting premiums and cost sharing for many beneficiaries and prohibiting cost sharing for certain groups and services. However, eligibility, managed-care rules, preferred-drug lists, prior authorization, and state policies can determine whether a particular medicine is accessible. Medicare Savings Programs, Extra Help, and state pharmaceutical-assistance programs can also change the real-world burden for people who qualify.

Drug-Cost Exposure—How Expensive Medicines Reach the Cap

Drug-cost exposure is the portion of a medicine’s price that reaches the patient after the insurer’s benefit design is applied. It is shaped less by the medicine’s list price alone than by its formulary tier, negotiated price, deductible status, coinsurance percentage, dispensing channel, and coverage category. IQVIA has reported that U.S. medicine spending is concentrated in specialty products, which often have high prices and complex administration even when they serve relatively small patient populations.

Deductibles create front-loaded costs

A deductible requires the patient to pay a specified amount before the plan begins paying for many covered services. A person who starts a high-cost therapy in January may pay the entire deductible immediately, followed by coinsurance. If the medicine is covered and consistently used, the patient may reach the out-of-pocket limit quickly; if treatment changes, coverage resets, or the drug is excluded, the expected protection may not materialize.

The Kaiser Family Foundation’s employer health-benefits surveys have consistently shown that deductibles and other cost sharing are common in job-based insurance. The average worker’s financial exposure is therefore not limited to the advertised monthly premium. For patients with chronic diseases, the timing of the deductible can be as important as the annual cap.

Coinsurance can be more volatile than copayments

A copayment is usually a fixed amount, while coinsurance is a percentage of the plan’s allowed amount. A $50 copayment is relatively predictable; 25% coinsurance on a $12,000 monthly specialty drug is not. Although the annual cap limits covered cost sharing, percentage-based benefits can create severe cash-flow pressure before the cap is reached.

The allowed amount also matters. Patients typically do not owe a percentage of the manufacturer’s list price; they owe the plan-defined cost-sharing amount. Yet a high allowed amount can still produce a large bill. For this reason, a graph comparing a medicine’s list price, negotiated price, patient coinsurance, and annual cap would show why a lower list price does not always translate into a lower immediate payment for a particular enrollee.

Formularies and specialty tiers determine whether the cap helps

A formulary is an insurer’s covered-drug list. Plans may place expensive biologics, gene therapies, and other specialty medicines on a specialty tier with coinsurance rather than a fixed copayment. They may also require step therapy, prior authorization, quantity limits, or use of a specialty pharmacy. These rules can delay treatment or require a patient to try a less expensive alternative before the prescribed medicine is covered.

A medicine that is excluded from the formulary can be financially different from a medicine that is expensive but covered. Covered cost sharing may count toward the cap; an excluded product often does not. Patients should therefore ask the plan whether the specific National Drug Code, dosage, site of administration, and benefit category are covered, rather than relying only on the drug’s brand name.

Cap Exclusions—Costs That Can Remain After the Limit

Cap exclusions are payments that do not reduce the patient’s remaining out-of-pocket maximum. They explain why reaching a cap does not always mean that all medical spending stops.

• Premiums usually continue after the out-of-pocket maximum is reached.
• Noncovered medicines and services may be paid entirely by the patient.
• Out-of-network care can produce separate deductibles, limits, or balance bills.
• Amounts above an insurer’s allowed charge may not count toward the cap.
• Over-the-counter products and some supplies may be excluded from the benefit.
• Travel, lost wages, transportation, and caregiving costs are not included in the insurance limit.

Manufacturer assistance is not the same as insurance protection

Copay cards and manufacturer coupons can reduce what an eligible commercially insured patient pays at the pharmacy, but they are not generally available to people enrolled in Medicare or Medicaid. In addition, some insurers use copay accumulators or maximizers. Under an accumulator design, manufacturer assistance may reduce the patient’s payment at the counter without reducing the amount credited toward the deductible or out-of-pocket maximum. A patient can therefore receive temporary relief and later face a renewed deductible obligation.

Independent charitable foundations and manufacturer patient-assistance programs may help uninsured or underinsured patients, but eligibility can depend on diagnosis, income, insurance status, available funding, and the medicine’s indication. Assistance should be treated as a separate layer of support rather than as proof that the underlying insurance design is affordable.

Medical debt and treatment decisions

The Consumer Financial Protection Bureau and academic health-policy researchers have documented the relationship between medical bills, debt, and delayed care. Prescription affordability is part of that problem: patients may skip doses, split pills when medically unsafe, delay refills, or stop treatment. A nominal annual cap cannot prevent harm if a patient cannot finance the first month of therapy or cannot obtain prior authorization in time.

The clinical consequences can be significant. For chronic conditions such as cancer, rheumatoid arthritis, multiple sclerosis, diabetes, and HIV, interruptions may reduce treatment effectiveness or increase the risk of hospitalization. The most useful measure is therefore not only whether a patient reaches the cap, but also whether the patient can obtain and continue the prescribed medicine throughout the year.

Patient Affordability—What the Cap Means in Practice

Patient affordability is the ability to pay for treatment without sacrificing basic needs or abandoning care. An out-of-pocket cap improves affordability by limiting worst-case covered spending, but it does not guarantee manageable monthly payments. Two people with the same medicine and the same annual cap may have very different experiences because of income, savings, plan year, family coverage, deductible timing, and access to assistance.

Example: commercial insurance

Consider a patient with a covered specialty drug and a commercial plan requiring a $3,000 deductible followed by 20% coinsurance, with a $9,200 individual out-of-pocket maximum. If the plan’s allowed drug cost is $10,000 per month, the patient may satisfy the deductible with the first prescription and then owe coinsurance until reaching the annual limit. The patient is protected from unlimited covered cost sharing, but may still need to find thousands of dollars during the first treatment cycle and pay the premium for the rest of the year.

Example: Medicare Part D

A Medicare beneficiary taking a covered oral cancer medicine may reach the $2,000 Part D limit much sooner than under the previous benefit structure. The payment-plan option can spread the obligation across the calendar year, improving cash flow. It does not reduce the total covered cost-sharing amount, however, and it does not solve problems involving formulary exclusion, prior authorization, or a medicine covered under Part B rather than Part D.

Questions patients should ask

1. Is the exact medicine covered, and under which benefit—pharmacy, medical, Part B, or Part D?
2. What are the deductible, coinsurance, copayment, and annual out-of-pocket limit?
3. Do covered drug payments count toward the cap, and are there separate pharmacy and medical limits?
4. Are prior authorization, step therapy, quantity limits, or specialty-pharmacy rules required?
5. What costs are excluded from the cap, including noncovered or out-of-network charges?
6. Can the insurer offer a payment plan, and can the prescriber’s office help with assistance or appeals?
7. Will changing plans or switching from individual to family coverage alter the deductible and limit?

Policy Reform—Why Caps Matter Beyond Individual Bills

Out-of-pocket caps are a form of financial risk protection. They redistribute some catastrophic medical risk from households to insurers and, ultimately, to premiums and public program spending. The Medicare Part D limit demonstrates how policy can convert an open-ended prescription-drug liability into a more predictable annual exposure. The Affordable Care Act’s limits similarly protect many commercially insured patients from unlimited in-network cost sharing.

Yet caps can also encourage insurers to manage expensive medicines through formularies, utilization review, and specialty tiers. Those tools may control premiums and overall spending, but they can create administrative barriers or shift costs toward people who need treatment most. Policymakers and employers evaluating a cap should therefore examine deductible levels, coinsurance, drug exclusions, accumulator policies, payment timing, and the percentage of patients who abandon prescriptions—not merely the dollar amount of the limit.

For consumers, the broader lesson is straightforward: an out-of-pocket maximum is a ceiling on eligible cost sharing, not a promise that every needed medicine will be affordable. Patients should verify coverage before filling a high-cost prescription, request a written estimate, appeal denials promptly, and seek help from a pharmacist, benefits administrator, clinician, or nonprofit patient-support organization.

Out-of-pocket caps—annual patient cost ceilings—protect against unlimited covered spending; commercial-plan caps set a high but finite liability; Medicare Part D’s prescription-drug limit offers a lower drug-specific ceiling; and drug-cost exposure, cap exclusions, and patient affordability determine the real outcome. The most effective approach combines a clear annual limit with predictable copayments, broad coverage of medically necessary medicines, timely authorization, payment-smoothing options, and assistance for people who cannot meet even a temporary bill. Consumers should read the plan’s Summary of Benefits and Coverage and drug formulary, while policymakers should measure whether caps improve continuous access to treatment rather than simply limiting the final annual bill.

Sources: Centers for Medicare & Medicaid Services, Out-of-Pocket Maximum/Limit, https://www.healthcare.gov/glossary/out-of-pocket-maximum-limit/; Centers for Medicare & Medicaid Services, 2025 Benefit Year Final Annual Limits on Cost Sharing, https://www.cms.gov/files/document/2025-papi-parameters-guidance.pdf; Medicare.gov, Medicare Part D Prescription Drug Coverage, https://www.medicare.gov/drug-coverage-part-d; Medicare.gov, Medicare Prescription Payment Plan, https://www.medicare.gov/prescription-payment-plan; Kaiser Family Foundation, 2024 Employer Health Benefits Survey, https://www.kff.org/report-section/ehbs-2024-summary-of-findings/; IQVIA Institute for Human Data Science, Global Use of Medicines 2024: Outlook to 2028, https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-use-of-medicines-2024-outlook-to-2028; Consumer Financial Protection Bureau, Medical Billing and Medical Debt, https://www.consumerfinance.gov/data-research/research-reports/medical-billing-and-medical-debt/